Enhancement of memory network activity in schizophrenia patients by phosphodiesterase-4 (PDE4) inhibitor, roflumilast: A pilot study
Published online on March 11, 2026
Abstract
Journal of Psychopharmacology, Ahead of Print.
Background:Cognitive impairments are prevalent in schizophrenia and are associated with functional outcomes, yet there are currently no approved treatments to address these deficits. Roflumilast, a phosphodiesterase 4 inhibitor, has previously been shown ...
Background:Cognitive impairments are prevalent in schizophrenia and are associated with functional outcomes, yet there are currently no approved treatments to address these deficits. Roflumilast, a phosphodiesterase 4 inhibitor, has previously been shown ...